secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123314
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q3 revenue $33.4M (up 26% YoY); cash $117.6M; pipeline programs advance
------------------------------------------------------------------------------

- Revenue $33.4M in Q3 2024, up from $26.4M in Q3 2023 (+26.5%).
- Cash & investments $117.6M as of Sep 30, 2024 (down from $137.2M at June 30); runway to end of 2025.
- CX-904 Phase 1a cleared 15 mg dose; Phase 1b possible in 2025 pending dose/schedule optimization.
- CX-2051 Phase 1a in colorectal cancer in fifth dose cohort; initial data expected H1 2025.
- CX-801 Phase 1a started, first patient dosed; initial data expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017024123314/0000950170-24-123314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017024123314/ctmx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer